


# Journal of Antimicrobial Chemotherapy

JAC

LATEST  
IMPACT FACTOR  
**5.068**



[www.jac.oxfordjournals.org](http://www.jac.oxfordjournals.org)

OXFORD  
UNIVERSITY PRESS

OXFORD  OPEN

# JAC

## The Journal of Antimicrobial Chemotherapy

---

### Editor-in-Chief

A. P. Johnson (London, UK)

### Senior Editors

J. P. Donnelly (Nijmegen, The Netherlands)

F. K. Gould (Newcastle upon Tyne, UK)

L. Leibovici (Petah-Tiqva, Israel)

R. L. Murphy (Chicago, USA)

D. S. Reeves (Bristol, UK)

S. Schwarz (Neustadt-Mariensee, Germany)

### Editorial Board

J. Ainsa (Zaragoza, Spain)

R. Anthony (Amsterdam, The Netherlands)

G. Biagini (Liverpool, UK)

P. G. Bray (Liverpool, UK)

P. Chandrasekar (Detroit, USA)

G. Davies (Liverpool, UK)

V. I. Enne (London, UK)

H. J. Field (Cambridge, UK)

G. Guaraldi (Modena, Italy)

A. Hill (Liverpool, UK)

R. Hope (London, UK)

K. L. Hopkins (London, UK)

M. Hornsey (London, UK)

P. J. Jenks (Plymouth, UK)

C. Kirkpatrick (Melbourne, Australia)

R. J. Koerner (Sunderland, UK)

P. D. Lister (Omaha, USA)

L. Maes (Antwerp, Belgium)

J.-Y. Maillard (Cardiff, UK)

V. Mallet (Paris, France)

J. Meletiadis (Athens, Greece)

L. Ostrosky-Zeichner (Houston, USA)

T. Parkinson (Sandwich, UK)

J. D. Perry (Newcastle upon Tyne, UK)

M. Peters (San Francisco, USA)

L. Poirel (Paris, France)

S. Pournaras (Larissa, Greece)

V. Ricci (Birmingham, UK)

K. K. Scarsi (Chicago, USA)

M. J. Schwaber (Tel Aviv, Israel)

E. Tacconelli (Rome, Italy)

B. Taiwo (Chicago, USA)

A. Thomson (Glasgow, UK)

A. Tsakris (Athens, Greece)

A. J. Ullmann (Würzburg, Germany)

E. van Duijkeren (Bilthoven,  
The Netherlands)

P. Wade (London, UK)

G. Werner (Wernigerode, Germany)

H. Wickens (London, UK)

A. Zolopa (Palo Alto, USA)

### Statistical Adviser

A. J. Hedges (Bristol, UK)

### Epidemiological Advisers

A. Fraser (Bristol, UK)

T. Lamagni (London, UK)

### Editorial Manager

C. W. E. Drummond

### Senior Staff Editor

C. L. Jeeves

### Staff Editor

S. Brockhouse

---

### Manuscript Submissions

All manuscripts should be submitted in electronic format via the Journal's online submission and refereeing system, which can be found at

<http://mc.manuscriptcentral.com/jac>

Details on how to submit a manuscript can be found in our Instructions to Authors (available at [http://www.oxfordjournals.org/jac/for\\_authors](http://www.oxfordjournals.org/jac/for_authors)). In addition to submitting your paper online you should simultaneously provide a written statement, signed by all the authors indicating that you have complied with the stipulations in the Instructions to Authors. A copy with the original signatures must be faxed to the Editorial Office as soon as possible after online submission. A blank form is available on the Instructions and Forms page of the JAC ScholarOne Manuscripts website.

Any authors who are genuinely unable to submit online should contact the Editorial Office.

JAC Editorial Office, Griffin House, 53 Regent Place, Birmingham, B1 3NJ, UK

Tel: +44 121 262 1830; Fax: +44 121 212 9822; E-mail: [jac@bsac.org.uk](mailto:jac@bsac.org.uk)

### Cover images (from top to bottom)

Ultrastructural morphology of swine  $\nu$  virus A/CA/4/09. Image credit CDC, C. S. Goldsmith and A. Balish.

Scanning electron micrograph of methicillin-resistant *Staphylococcus aureus*. Image credit CDC, Janice Haney Carr/Jeff Hageman MHS.

*Trypanosoma brucei* parasites in a thin film blood smear. Image credit CDC, Dr Mae Melvin.

Mature *Mucor* sporangium. Image credit CDC, Dr Lucille K. Georg.



Scan to view this journal on  
your mobile device

## The Journal of Antimicrobial Chemotherapy

### Subscription information

A subscription to *The Journal of Antimicrobial Chemotherapy* comprises 12 issues plus supplements. Subscriptions are entered on a calendar year basis only. Please add sales tax to prices quoted. Price includes postage by surface mail or for subscribers in the USA and Canada by air freight or in India, Japan, Australia and New Zealand, by Air Speeded Post. Airmail rates are available on request. *The Journal of Antimicrobial Chemotherapy Advance Access* contains papers that have recently reached corrected proof stage, but have not yet been included within an issue. Advance Access is updated weekly.

### Annual subscription rate (Volume 67, 2012)

#### Institutional.

Print edition and site-wide online access: £929.00/\$1765.00/€1394.00.

Print edition only: £851.00/\$1702.00/€1278.00.

Site-wide online access only: £722.00/\$1444.00/€1083.00.

#### Personal.

Print edition and individual online access: £468.00/\$936.00/€702.00.

Site-wide online access only: £415.00/\$830.00/€622.00.

Please note: US\$ rate applies to US and Canada, Euros applies to Europe, UK£ applies to UK and Rest of World. There may be other subscription rates available, for a complete listing please visit [www.jac.oxfordjournals.org/subscriptions](http://www.jac.oxfordjournals.org/subscriptions). Full prepayment in the correct currency is required for all orders. Payment should be in US dollars for orders being delivered to the USA or Canada; Euros for orders being delivered within Europe (excluding the UK); GBP Sterling for orders being delivered elsewhere (i.e., not being delivered to USA, Canada, or Europe). All orders should be accompanied by full payment and sent to your nearest Oxford Journals office. Subscriptions are accepted for complete volumes only. Orders are regarded as firm, and payments are not refundable. Our prices include dispatch by Standard Air. Claims must be notified within four months of despatch/order date (whichever is later). Subscriptions in the EEC may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Subscribers in Canada, please add GST to the prices quoted. Personal rate subscriptions are only available if payment is made by personal cheque or credit card, delivery is to a private address, and is for personal use only.

The current year and two previous years' issues are available from Oxford Journals. Previous volumes can be obtained from the Periodicals Service Company at <http://www.periodicals.com/oxford.html> or Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. E-mail: [psc@periodicals.com](mailto:psc@periodicals.com). Tel: (518) 537-4700. Fax: (518) 537-5899.

**For further information, please contact:** Journals Customer Service Department, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. E-mail: [jnl.cust.serv@oup.com](mailto:jnl.cust.serv@oup.com). Tel (and answerphone outside normal working hours): +44 (0)1865 353907. Fax: +44 (0)1865 353485. **In the Americas, please contact:** Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513, USA. E-mail: [jnlorders@oup.com](mailto:jnlorders@oup.com). Tel (and answerphone outside normal working hours): 800 852 7323 (toll-free in USA/Canada). Fax: 919 677 1714. **In Japan, please contact:** Oxford University Press, Tokyo 4-5-10-8F Shiba, Minato-ku, Tokyo 108-8386 Japan. Email: [custserv.jp@oup.com](mailto:custserv.jp@oup.com). Tel: +81 3 5444 5858. Fax: +81 3 3454 2929.

**Methods of payment.** Payment should be made by: (i) Cheque (payable to Oxford University Press, to Oxford University Press, Cashiers Office, Great Clarendon Street, Oxford OX2 6DP, UK) in GB£ Sterling (drawn on a UK bank), US\$ Dollars (drawn on a US bank), or EU€ Euros. (ii) Bank transfer to Barclays Bank Plc, Oxford Group Office, Oxford (bank sort code 20-65-18) (UK), overseas only Swift code BARC GB22 (GB£ Sterling to account no. 70299332, IBAN GB89BARC 20651870299332; US\$ Dollars to account no. 66014600, IBAN GB27BARC

20651866014600; EU€ Euros to account no. 78923655, IBAN GB16BARC 20651878923655). (iii) Credit card (Mastercard, Visa, Switch or American Express).

### Advertising

Advertising, inserts and artwork enquiries should be addressed to: Advertising and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax +44 (0)1865 353774; E-mail: [jnladsadvertising@oup.com](mailto:jnladsadvertising@oup.com)

### Supplements, Reprints, and Corporate Sales

Requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation possibilities for previously published material, networked online international office subscriptions, and other online opportunities. Contact: [Special.Sales@oup.com](mailto:Special.Sales@oup.com), fax: +44 (0)1865 353774, or visit [www.oxfordjournals.org/corporate\\_services/index.html](http://www.oxfordjournals.org/corporate_services/index.html)

### Environmental and ethical policies

Oxford Journals, a division of Oxford University Press, is committed to working with the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementing environmentally friendly policies and practices wherever possible. Please see <http://www.oxfordjournals.org/ethicalpolicies.html> for further information on environmental and ethical policies.

### Copyright

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without either the prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Centre, 222 Rosewood Drive, Danvers, MA 01923. For those in the US/Canada not registered with CCC, articles can be obtained by fax in 48 hours by calling: WISE for Medicine™ 1-800-667-WISE. Special requests, such as copying for general distribution or for advertising or promotional purposes, should be addressed to the Production Editor, *The Journal of Antimicrobial Chemotherapy*, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK.

*The Journal of Antimicrobial Chemotherapy* (ISSN 0305-7453) is published monthly by Oxford University Press, Oxford, UK. Annual subscription price is £929.00/\$1765.00/€1394.00. Airfreight and mailing in the USA by agent named Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146<sup>th</sup> Avenue, 2<sup>nd</sup> Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Jamaica NY 11431.

US Postmaster: send address changes to *The Journal of Antimicrobial Chemotherapy*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146<sup>th</sup> Avenue, 2<sup>nd</sup> Floor, Jamaica, NY 11434, USA.

**Journal disclaimer.** The mention of trade names, commercial products or organizations, and the inclusion of advertisements in the journal does not imply endorsement by the *Journal of Antimicrobial Chemotherapy*, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. All reasonable precautions have been taken by the authors, editors and publishers to verify drug names and doses, the results of experimental work and the clinical findings published in this journal. The opinions expressed are those of the authors, and not necessarily those of the editors or publishers. The ultimate responsibility for the use and dosage of drugs mentioned in the Journal and in the interpretation of published material lies with the medical practitioner and the editors and publishers cannot accept liability for damages arising from any errors or omissions in the journal. Please inform the editors of any errors.

© 2012 The British Society for Antimicrobial Chemotherapy  
Typeset by the Techset Composition Ltd, Salisbury, UK  
Printed by Bell and Bain Ltd, Glasgow, UK



## Antimicrobial activity of copper surfaces against carbapenemase-producing contemporary Gram-negative clinical isolates

Maria Souli<sup>1\*</sup>, Irene Galani<sup>1</sup>, Diamantis Plachouras<sup>1</sup>, Theofano Panagea<sup>1†</sup>, Apostolos Armaganidis<sup>2</sup>, George Petrikos<sup>1</sup> and Helen Giamarellou<sup>1‡</sup>

<sup>1</sup>4th Department of Internal Medicine, Athens University School of Medicine, University General Hospital 'Attikon', 1 Rimini Str. 124 62, Chaidari, Athens, Greece; <sup>2</sup>2nd Department of Critical Care Medicine, Athens University School of Medicine, University General Hospital 'Attikon', 1 Rimini Str. 124 62, Chaidari, Athens, Greece

\*Corresponding author. Tel: +302105831643; Fax: +302105326446; E-mail: msouli@med.uoa.gr

†Present address: Microbiology Department, 'Amalia Fleming' General Hospital, 14 March 25th St., Melissia, Athens, Greece.

‡Present address: 6th Department of Internal Medicine, Diagnostic and Therapeutic Center of Athens 'Hygeia', 4 Erythrou Stravrou St. and Kifissias Av., Maroussi, Athens, Greece.

Received 30 August 2012; returned 4 October 2012; revised 18 October 2012; accepted 31 October 2012

**Objectives:** The antimicrobial activity of copper surfaces against a variety of contemporary carbapenemase-producing Gram-negative bacteria representative of the most problematic nosocomial pathogens worldwide was evaluated.

**Methods:** Twenty-four clinical isolates, comprising four of *Escherichia coli*, two of *Enterobacter* spp., eight of *Klebsiella pneumoniae* and five each of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* producing either VIM-1 and/or KPC-2 or VIM-2 or OXA-type carbapenemases, were studied. The antimicrobial activity of 99% copper (Cu99%) and a 63% alloy (Cu63%) was evaluated in comparison with that of stainless steel (SS) and polyvinylchloride (PVC) by incubating  $\sim 10^6$  cfu/cm<sup>2</sup> of the tested strains on each surface at room temperature.

**Results:** Copper demonstrated antimicrobial activity against all studied isolates. This effect was observed earlier and was more pronounced for Cu99% than for Cu63%. Cu99% showed a bactericidal effect after <2 h for *A. baumannii*, 3 h for *Enterobacter* spp., 5 h for *K. pneumoniae* and 6 h for *P. aeruginosa* and *E. coli*. No viable colonies were recovered from five (20.8%) isolates after 3 h and from nine (37.5%) isolates after 5 h of incubation on Cu99%.

**Conclusions:** Copper has significant antimicrobial activity against multidrug-resistant nosocomial Gram-negative pathogens. This supports the hypothesis that replacement of high-contact materials with copper could reduce the high burden of environmental contamination around high-risk patients. However, this strategy should be seen as an adjunctive measure to established cleaning protocols and to good hygiene practices for prevention of hospital-acquired infections.

**Keywords:** multidrug resistant, *K. pneumoniae*, *P. aeruginosa*, *Acinetobacter*, *Enterobacter* spp.

### Introduction

The sanitizing properties of copper (Cu) have been known and exploited since ancient times, but they have received renewed attention over recent decades as laboratory studies have shown that various bacteria, yeasts and viruses are rapidly killed on metallic copper surfaces by 'contact killing'.<sup>1</sup>

Living organisms require copper at low concentrations as cofactors for metalloproteins and enzymes. However, at high

concentrations, Cu(II) exhibits a toxic effect on most microorganisms. Various species have already been tested, including *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Salmonella enterica*, *Campylobacter jejuni*, *Escherichia coli* 0157, *Acinetobacter baumannii*, *Clostridium difficile* and influenza virus as well as *Candida albicans* and a variety of moulds, all with positive results.<sup>1</sup> This led to the registration of 300 different copper alloys as antimicrobial surfaces by the US Environmental Protection Agency in 2008.<sup>2</sup>

The mechanism of contact killing has been the subject of research, and, although it is not yet fully elucidated, a number of contributing factors have been identified. As well as reactive oxygen species, surface-released free copper ions play an important role in contact killing, probably generated by redox cycling between the different copper species, Cu(0), Cu(I) and Cu(II). In the current state of knowledge, it appears that contact killing proceeds by successive membrane damage, copper influx into the cells, oxidative damage, cell death and DNA degradation.<sup>3–5</sup>

In the past decade there has been an alarming emergence of multidrug-resistant (MDR), mainly carbapenem-resistant, Gram-negative bacteria in the hospital environment around the world. These strains have been extremely difficult to contain and they have been very difficult to treat once they have caused clinical infections.<sup>6</sup> The aim of the present study was to evaluate the antimicrobial activity of copper surfaces against a variety of contemporary MDR Gram-negative isolates representative of the most problematic nosocomial pathogens worldwide.

## Methods

### Bacterial strains

Gram-negative clinical isolates were used in the study if they were MDR, i.e. if they were resistant to at least three groups of relevant antibiotics. These were isolated from various specimens of patients hospitalized in University General Hospital 'Attikon'. Species identification and MIC determinations were performed using an automated system (BD Phoenix automated microbiology system; BD Diagnostic Systems, Sparks, MD, USA). Results were interpreted according to CLSI criteria,<sup>7</sup> with the exception of those for fosfomycin and colistin. For these agents, the breakpoints proposed by EUCAST<sup>8</sup> were used (susceptibility  $\leq 32$  mg/L for fosfomycin against Enterobacteriaceae and  $\leq 2$  or  $\leq 4$  mg/L for colistin against Enterobacteriaceae and *Acinetobacter* spp. or against *P. aeruginosa*, respectively) because relevant breakpoints were not available from the CLSI.

The EDTA–imipenem disc synergy test was performed for the phenotypic detection of metallo- $\beta$ -lactamase production<sup>9</sup> and the imipenem–boronic acid disc synergy test was used for the detection of production of KPC carbapenemase in Enterobacteriaceae.<sup>10</sup> PCR with specific primers was used for confirmation of the presence of *bla*<sub>VIM</sub>, *bla*<sub>KPC</sub> or *bla*<sub>OXA</sub> genes.<sup>11–13</sup>

**Table 1.** Susceptibilities of the studied isolates to selected antimicrobial agents

Antimicrobial agent	MIC range (mg/L)	Susceptibility (%)
Amikacin	$\leq 8$ to $> 32$	20.8
Gentamicin	$\leq 2$ to $> 8$	41.7
Aztreonam <sup>a</sup>	$\leq 2$ to $> 16$	5.3
Cefepime <sup>b</sup>	16 to $> 16$	0
Imipenem	$\leq 1$ to $> 8$	8.3
Ciprofloxacin	$\leq 0.5$ to $> 2$	25
Trimethoprim/sulfamethoxazole <sup>b</sup>	$\leq 1/19$ to $> 2/38$	21.4
Fosfomycin <sup>b</sup>	$\leq 16$ to 128	78.6
Colistin	$\leq 0.5$ to $> 4$	87.5

<sup>a</sup>Only Enterobacteriaceae and *P. aeruginosa* isolates were evaluated.

<sup>b</sup>Only Enterobacteriaceae were evaluated.

### Metal coupons

To assess the antimicrobial activity of copper, we used metal coupons (1×1 cm) containing either 99% Cu (Cu99%) or a brass alloy containing 63% Cu and 37% Zn (Cu63%). Similar size coupons of stainless steel (SS) or polyvinylchloride (PVC) were used as controls. Metal coupons were supplied by the Hellenic Copper Development Institute and prior to use they were degreased and cleaned by vortexing in acetone for 30 s, immersion in absolute ethanol and flaming in a Bunsen burner. PVC coupons were only immersed in absolute ethanol and allowed to dry. All coupons were stored in sterile Petri dishes.

### Bacterial viability experiments

On the day of the experiment, a bacterial suspension with a turbidity equivalent to that of a 0.5 McFarland standard was made from pure colonies of an overnight culture of each isolate. Twenty microlitres of this suspension ( $\sim 10^6$  cfu) was inoculated on each of the four coupons, which were then incubated at room temperature (20–25°C) for 0, 1, 2, 3, 5, 6 and 24 h. Time 0 was considered the time that the droplet was placed on the coupon. At each time interval, each coupon was aseptically removed and immersed into 10 mL of sterile Dey/Engley (D/E) broth (BD Diagnostic Systems) to neutralize any further antimicrobial activity of copper.<sup>14</sup> Coupons were vortexed for 60 s and 0.1 mL of broth was removed and serially diluted 10-fold in sterile PBS. Twenty-five microlitres of each dilution was plated onto MacConkey agar (BD Diagnostic Systems) plates and incubated at 37°C for 18 h for colony counting. Results were expressed as  $\log_{10}$  cfu/cm<sup>2</sup>. The lower limit of detection was 2.6  $\log_{10}$  cfu/cm<sup>2</sup>.

The survival over time on each of the surfaces was expressed as mean  $\log_{10}$  cfu/cm<sup>2</sup> of all isolates of the same species at each timepoint. In cases where no viable colonies were detected, the lower limit of detection was used in calculations. Bacteriostatic activity was defined as a  $\geq 2$  to  $< 3$   $\log_{10}$  reduction and bactericidal activity as a  $\geq 3$   $\log_{10}$  reduction in the cfu from the inoculum at time 0 on that surface.

### Statistical analysis

One-way analysis of variance was used to compare  $\log_{10}$  cfu/cm<sup>2</sup> at each timepoint among the four studied surfaces and *post hoc* analysis was performed by the Bonferroni method. All differences with  $P < 0.05$  were considered statistically significant. All statistical analyses were done using IBM SPSS Statistics 20 software.

### Ethics

Ethical approval was not required.

## Results

The 24 clinical isolates that were used in the experiments comprised four isolates of *E. coli* (three KPC-2 producers and one VIM-1 producer), two isolates of *Enterobacter* spp. (one KPC-2 producer and one KPC-2/VIM-1 producer), eight isolates of *Klebsiella pneumoniae* (seven KPC-2 producers and one VIM-1 producer), five isolates of VIM-2-producing *P. aeruginosa* and five isolates of *A. baumannii* (two OXA-51 and three OXA-51/OXA-58 producers). These isolates were recovered from blood (eight isolates), bronchial secretions (six isolates), faecal flora (seven isolates), urine (two isolates) and pus (one isolate) of hospitalized patients.

All tested isolates were resistant to second- and third-generation cephalosporins and  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations. The susceptibilities of the studied isolates to

various antimicrobial agents are presented in Table 1 and in Table S1 (available as Supplementary data at JAC Online).

The survival of test organisms on each surface over time was expressed as the difference between the mean starting inoculum and the mean viable cell count at each time interval of all isolates of the same species ( $\Delta \log_{10}$  cfu/cm<sup>2</sup>). A negative sign represented a reduction and a positive sign an increase from the inoculum at time 0. Results are shown in Table 2 and Table S2 (available as Supplementary data at JAC Online). Time-kill curves were constructed for each group of isolates of the same species by plotting the mean  $\log_{10}$  cfu/cm<sup>2</sup> over time (Figure 1a–e).

For the group of four *E. coli* isolates, Cu99% demonstrated a reduction of initial inoculum by 2  $\log_{10}$  cfu/cm<sup>2</sup> at 3 h of incubation in indoor conditions and a bactericidal effect at 6 h, whereas none of the other surfaces showed bactericidal activity during the first 6 h. A bactericidal effect was shown for Cu63% at 24 h (Table 2 and Figure 1a). For the group of two *Enterobacter*

**Table 2.** Difference between mean starting inoculum and mean viable cell count ( $\Delta \log_{10}$  cfu/cm<sup>2</sup>) of the four *E. coli*, the two *Enterobacter* spp., the eight *K. pneumoniae*, the five *P. aeruginosa* and the five *A. baumannii* isolates at each time interval

Surface material	Time (h)					
	1	2	3	5	6	24
$\Delta \log_{10}$ cfu/cm <sup>2</sup> for <i>E. coli</i> isolates						
Cu99%	0.21	-0.13	-2.00	-2.81	-4.15	-4.15
Cu63%	0.09	0.15	0.32	-0.81	-2.90	-3.67
SS	0.06	0.07	0.51	-0.01	-0.41	-1.87
PVC	-0.17	0.38	0.47	-0.60	0.67	-2.39
$\Delta \log_{10}$ cfu/cm <sup>2</sup> for <i>Enterobacter</i> spp. isolates						
Cu99%	-0.02	-0.13	-4.74*	-4.76*	-4.74	-4.74*
Cu63%	-0.20	0.34	-0.06	-3.36*	-4.60	-4.60*
SS	-0.07	0.05	0.12	-0.69	-3.59	-4.70*
PVC	0.12	0.07	0.63	-0.68	-0.04	-2.35
$\Delta \log_{10}$ cfu/cm <sup>2</sup> for <i>K. pneumoniae</i> isolates						
Cu99%	0.03	0.03	0.22	-3.29*	-3.72*	-4.05*
Cu63%	-0.08	0.15	0.32	-2.00	-2.34	-3.96*
SS	0.13	0.12	0.80	-0.65	-2.01	-3.39*
PVC	0.07	0.16	0.68	0.04	-0.34	-2.25
$\Delta \log_{10}$ cfu/cm <sup>2</sup> for <i>P. aeruginosa</i> isolates						
Cu99%	NE	-1.61	-2.08	-2.71*	-3.70*	-4.59*
Cu63%	NE	-0.97	-1.52	-1.87*	-1.56	-3.09
SS	NE	-0.40	-0.57	-1.06	-1.18	-1.54
PVC	NE	-0.15	-0.39	-0.82	-0.53	-2.09
$\Delta \log_{10}$ cfu/cm <sup>2</sup> for <i>A. baumannii</i> isolates						
Cu99%	NE	-3.74*	-3.12*	-3.31*	-3.76*	-4.56*
Cu63%	NE	-1.98	-1.61*	-2.67*	-2.98	-3.91
SS	NE	-0.64	-0.77	-0.79	-0.87	-1.01
PVC	NE	-0.78	-1.10	-1.11	-1.31	-1.69

NE, values at 1 h were not evaluated; Cu99%, pure copper; Cu63%, copper alloy.

A negative sign represents a reduction and a positive sign an increase from the inoculum at time 0. Asterisks denote differences that were statistically significant in the within-group comparisons.

spp., a bactericidal effect was detected at 3 h for Cu99% and at 5 h for Cu63%. Among the control surfaces, SS showed a bactericidal effect after 6 h (Table 2 and Figure 1b). Against the group of eight *K. pneumoniae* isolates, a bactericidal effect was demonstrated by 5 h for Cu99%. Cu63% reduced the initial inoculum by 2  $\log_{10}$  cfu/cm<sup>2</sup> at 5 h. Cu63% and SS showed a bactericidal effect at 24 h (Table 2 and Figure 1c). Cu99% reduced the initial inoculum of *P. aeruginosa* by 2.08  $\log_{10}$  cfu/cm<sup>2</sup> at 3 h, but a bactericidal effect was shown at 6 h. Cu63% showed a bactericidal effect after 24 h (Table 2 and Figure 1d). Against *A. baumannii*, the bactericidal effect of Cu99% was shown in <2 h, whereas that of Cu63% was evident after 6 h. Neither of the control surfaces showed a significant reduction of viable cells even at 24 h (Table 2 and Figure 1e).


Comparing the antimicrobial activity of Cu99% with that of copper alloy for the whole collection of studied isolates, we observed an earlier and more pronounced antimicrobial effect of Cu99% versus Cu63% (a median of 3 versus 5 h for a bacteriostatic effect and 5 versus 24 h for a bactericidal effect). No viable colonies were recovered from five (20.8%) isolates (two *Enterobacter* spp. and one each of *E. coli*, *P. aeruginosa* and *A. baumannii*) after 3 h and from nine (37.5%) isolates (six *K. pneumoniae*, two *E. coli* and one *A. baumannii*) after 5 h of incubation on Cu99% in indoor conditions. For all groups of isolates, Cu99% demonstrated a statistically significant effect at 3 h compared with all other surfaces [ $F(79.1,209.1) = 12.11$ ,  $P < 0.001$ ]. This effect persisted throughout the experiment and remained significant in comparison with SS and PVC, but in comparison with the alloy a significant difference was noted at 3 and 5 h only. The effect of the copper alloy was significant from 6 h onwards compared with PVC and from 24 h compared with SS.

## Discussion

Carbapenemase-producing Gram-negative organisms have become endemic in hospital settings in several geographical regions and have been reported to cause important nosocomial outbreaks in others. High morbidity and mortality rates have been observed in relation to infections by these strains.<sup>15</sup> The containment of carbapenemase producers has been the focus of guidelines issued by several expert committees, but despite these efforts the prevalence rates of carbapenem-resistant bacteria have been increasing.<sup>6,16</sup> There is definitely a need for new approaches in the field of infection control and antimicrobial copper could provide one such approach to supplement the current measures for prevention of dissemination of MDR strains in hospitals.

Currently, the antimicrobial activities of a variety of copper alloys have been successfully evaluated in the laboratory<sup>1</sup> and in hospital settings against various Gram-negative bacteria, but not against carbapenemase producers.<sup>17,18</sup> The present study was conducted to investigate whether a variety of carbapenemase-producing Gram-negative bacteria representative of the contemporary 'hospital nightmares' were susceptible to the antimicrobial properties of copper surfaces.

We observed a significant effect of metallic copper alloys against all tested species. This effect was exerted earlier and was more pronounced for Cu99% than for the Cu63% alloy. Nevertheless, survival was longer than that observed in studies



**Figure 1.** Survival over time of four *E. coli* (a), two *Enterobacter* spp. (b), eight *K. pneumoniae* (c), five *P. aeruginosa* (d) and five *A. baumannii* (e) isolates on copper (Cu99%), copper alloy (Cu63%), SS or PVC. Points represent the mean number of viable colonies for each group of isolates.

evaluating susceptible strains. For example, *E. coli* was inactivated within a few minutes,<sup>19</sup> *P. aeruginosa* after 120 min<sup>20</sup> and *A. baumannii* after 180 min of exposure to copper.<sup>21</sup> Although factors related to the resistance genes cannot be

excluded, we believe that factors related to the methodology could probably account for these differences. It has been shown that higher copper content of alloys,<sup>20</sup> higher temperature,<sup>20,22</sup> higher relative humidity<sup>23</sup> and a 'dry' as opposed to a




Figure 1. Continued

'wet' inoculation technique<sup>4,24</sup> increased the efficacy of contact killing. It was shown by Elguindi et al.<sup>20</sup> that the survival of *P. aeruginosa* PAO1 was shortened by 2 h when the inoculum was spread on the copper coupon instead of being left as a droplet, but the results were reproducible only when the 'droplet' technique was used. Furthermore, when a cotton swab was used to spread the inoculum evenly on tested surfaces, the amount of bacteria left on the surface was not standardized. We decided to apply the droplet inoculation technique, which was most often used in related published literature in order to obtain reproducible results and to be able to compare our results with previous studies.

Control SS surfaces exhibited a  $-3.59 \log_{10}$  cfu/cm<sup>2</sup> change in initial inoculum of *Enterobacter* spp. at 6 h and a  $-3.39 \log_{10}$  cfu/cm<sup>2</sup> change in the inoculum of *K. pneumoniae* at 24 h and control PVC surfaces a  $-2.09$  to  $-2.39 \log_{10}$  cfu/cm<sup>2</sup> change in initial inoculum of *E. coli*, *Enterobacter* spp., *K. pneumoniae* and *P. aeruginosa* at 24 h. These reductions represented the inherent incapability of these species of surviving on dry surfaces over time, in contrast to *A. baumannii*. Michels et al.<sup>25</sup> showed a similar effect after exposure of *E. coli* on SS for  $\geq 24$  h.

The killing of carbapenemase-producing MDR Gram-negative bacteria on copper surfaces suggests that the use of copper

alloys in high-contact surfaces in the hospital may offer the potential to reduce the spread of 'difficult-to-treat' nosocomial pathogens, if coupled with optimal cleaning procedures and compliance with infection-control practices. Clinical studies showing reduction in cross-transmission as well as reduction in nosocomial infection rates in settings with high prevalences of carbapenemase producers would be welcomed by the medical community.

## Acknowledgements

Some of these data were presented at the Twenty-first European Congress of Clinical Microbiology and Infectious Disease/Twenty-seventh International Congress of Chemotherapy, Milan, Italy, 2011 (R2586).

We wish to thank Zoi Chryssouli for outstanding technical work.

## Funding

This study was supported in part by the Hellenic Copper Development Institute.



## Transparency declarations

G. P. and A. A. have received a research grant from the Hellenic Copper Development Institute. All other authors: none to declare.

## Supplementary data

Tables S1 and S2 are available as Supplementary data at JAC Online (<http://jac.oxfordjournals.org/>).

## References

- Grass G, Rensing C, Solioz M. Metallic copper as an antimicrobial surface. *Appl Environ Microbiol* 2011; **77**: 1541–7.
- US Environmental Protection Agency. <http://www.epa.gov/pesticides/factsheets/copper-alloy-products.htm> (20 August 2012, date last accessed).
- Espirito Santo C, Lam EW, Elowsky CG *et al.* Bacterial killing by dry metallic copper surfaces. *Appl Environ Microbiol* 2011; **77**: 794–802.
- Espirito Santo C, Taudte N, Nies DH *et al.* Contribution of copper ion resistance to survival of *Escherichia coli* on metallic copper surfaces. *Appl Environ Microbiol* 2008; **74**: 977–86.
- Warnes SL, Green SM, Michels HT *et al.* Biocidal efficacy of copper alloys against pathogenic enterococci involves degradation of genomic and plasmid DNA. *Appl Environ Microbiol* 2010; **76**: 5390–401.
- Carmeli Y, Akova M, Cornaglia G *et al.* Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. *Clin Microbiol Infect* 2010; **16**: 102–11.
- Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21*. CLSI, Wayne, PA, USA, 2011.
- EUCAST. *Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 2.0, 2012-01-01*. [http://www.eucast.org/clinical\\_breakpoints](http://www.eucast.org/clinical_breakpoints) (20 August 2012, date last accessed).
- Lee K, Chong Y, Shin HB *et al.* Modified Hodge and EDTA-disk synergy tests to screen metallo- $\beta$ -lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species. *Clin Microbiol Infect* 2001; **7**: 88–91.
- Tsakris A, Kristo I, Poulou A *et al.* Evaluation of boronic acid disk tests for differentiating KPC-possessing *Klebsiella pneumoniae* in the clinical laboratory. *J Clin Microbiol* 2009; **47**: 362–7.
- Koratzanis E, Souli M, Galani I *et al.* Epidemiology and molecular characterisation of metallo- $\beta$ -lactamase-producing Enterobacteriaceae in a university hospital intensive care unit in Greece. *Int J Antimicrob Agents* 2011; **38**: 390–7.
- Souli M, Galani I, Antoniadou A *et al.* An outbreak of infection due to  $\beta$ -lactamase *Klebsiella pneumoniae* carbapenemase 2-producing *K. pneumoniae* in a Greek university hospital: molecular characterization, epidemiology, and outcomes. *Clin Infect Dis* 2010; **50**: 364–73.
- Woodford N, Ellington MJ, Coelho JM *et al.* Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents* 2006; **27**: 351–3.
- Wheeldon LJ, Worthington T, Lambert PA *et al.* Antimicrobial efficacy of copper surfaces against spores and vegetative cells of *Clostridium difficile*: the germination theory. *J Antimicrob Chemother* 2008; **62**: 522–5.
- Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis* 2011; **17**: 1791–8.
- Siegel JD, Rhinehart E, Jackson M *et al.* Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. *Am J Infect Control* 2007; **35** Suppl 2: S165–93.
- Schmidt MG, Attaway HH, Sharpe PA *et al.* Sustained reduction of microbial burden on common hospital surfaces through the introduction of copper. *J Clin Microbiol* 2012; **50**: 2217–3.
- Casey AL, Adams D, Karpenen TJ *et al.* Role of copper in reducing hospital environment contamination. *J Hosp Infect* 2010; **74**: 72–7.
- Espirito Santo C, Morais PV, Grass G. Isolation and characterization of bacteria resistant to metallic copper surfaces. *Appl Environ Microbiol* 2010; **76**: 1341–8.
- Elguindi J, Wagner J, Rensing C. Genes involved in copper resistance influence survival of *Pseudomonas aeruginosa* on copper surfaces. *J Appl Microbiol* 2009; **106**: 1448–55.
- Mehtar S, Wiid I, Todorov SD. The antimicrobial activity of copper and copper alloys against nosocomial pathogens and *Mycobacterium tuberculosis* isolated from healthcare facilities in the Western Cape: an *in vitro* study. *J Hosp Infect* 2008; **68**: 45–51.
- Michels HT, Noyce JO, Keevil CW. Effects of temperature and humidity on the efficacy of methicillin-resistant *Staphylococcus aureus* challenged antimicrobial materials containing silver and copper. *Lett Appl Microbiol* 2009; **49**: 191–5.
- Wilks SA, Michels HT, Keevil CW. The survival of *Escherichia coli* O157 on a range of metal surfaces. *Int J Food Microbiol* 2005; **105**: 445–54.
- Elguindi J, Moffitt S, Hasman H *et al.* Metallic copper corrosion rates, moisture content and growth medium influence survival of copper ion-resistant bacteria. *Appl Microbiol Biotechnol* 2011; **89**: 1963–70.
- Michels HT, Moran W, Michel J. Antimicrobial properties of copper alloy surfaces, with a focus on hospital-acquired infections. *Advanced Materials & Processes® Web Exclusive*. November 2008; doi:10.1361/amp1108copper.